Tumor Necrosis Factor α: Taking a Personalized Road in Cancer Therapy

Overview

Journal Front Immunol

Specialty Allergy & Immunology

Date 2022 Jun 6

PMID 35663982

Authors

Adit Ben-Baruch

Affiliations

Soon will be listed here.

Citing Articles

In situ blockade of TNF-TNFR2 axis via oncolytic adenovirus improves antitumor efficacy in solid tumors.

Kang X, Han Y, Wu M, Li Y, Qian P, Xu C Mol Ther. 2024; 33(2):670-687.

PMID: 39690741 PMC: 11853363. DOI: 10.1016/j.ymthe.2024.12.011.

Apoptotic signaling by TNFR1 is inhibited by the α2-6 sialylation, but not α2-3 sialylation, of the TNFR1 N-glycans.

Hwang J, Rao T, Tao J, Sha B, Narimatsu Y, Clausen H J Biol Chem. 2024; 301(1):108043.

PMID: 39615678 PMC: 11732462. DOI: 10.1016/j.jbc.2024.108043.

Chemotherapy combined with Shenmai injection alleviates inflammatory response and side effects in the patients with advanced colorectal cancer: A retrospective analysis.

Jin Y, Zhu W, Dai H, He X Pak J Med Sci. 2024; 40(9):1953-1957.

PMID: 39416603 PMC: 11476158. DOI: 10.12669/pjms.40.9.9881.

Tumor-produced immune regulatory factors as a therapeutic target in cancer treatment.

Rogovskii V Front Immunol. 2024; 15:1416458.

PMID: 39206193 PMC: 11349530. DOI: 10.3389/fimmu.2024.1416458.

The molecular conversations of sarcomas: exosomal non-coding RNAs in tumor's biology and their translational prospects.

Luongo M, Laurenziello P, Cesta G, Bochicchio A, Omer L, Falco G Mol Cancer. 2024; 23(1):172.

PMID: 39174949 PMC: 11340101. DOI: 10.1186/s12943-024-02083-y.

References

Balkwill F, Lee A, Aldam G, Moodie E, Thomas J, Tavernier J . Human tumor xenografts treated with recombinant human tumor necrosis factor alone or in combination with interferons. Cancer Res. 1986; 46(8):3990-3. View

Brouckaert P, Leroux-Roels G, Guisez Y, Tavernier J, Fiers W . In vivo anti-tumour activity of recombinant human and murine TNF, alone and in combination with murine IFN-gamma, on a syngeneic murine melanoma. Int J Cancer. 1986; 38(5):763-9. DOI: 10.1002/ijc.2910380521. View

Smith C, Davis T, Anderson D, Solam L, Beckmann M, Jerzy R . A receptor for tumor necrosis factor defines an unusual family of cellular and viral proteins. Science. 1990; 248(4958):1019-23. DOI: 10.1126/science.2160731. View

Balkwill F . The chemokine system and cancer. J Pathol. 2011; 226(2):148-57. DOI: 10.1002/path.3029. View

Li Y, Zhu G, Zhai H, Jia J, Yang W, Li X . Simultaneous stimulation with tumor necrosis factor-α and transforming growth factor-β1 induces epithelial-mesenchymal transition in colon cancer cells via the NF-κB pathway. Oncol Lett. 2018; 15(5):6873-6880. PMC: 5920468. DOI: 10.3892/ol.2018.8230. View

Madhusudan S, Foster M, Muthuramalingam S, Braybrooke J, Wilner S, Kaur K . A phase II study of etanercept (Enbrel), a tumor necrosis factor alpha inhibitor in patients with metastatic breast cancer. Clin Cancer Res. 2004; 10(19):6528-34. DOI: 10.1158/1078-0432.CCR-04-0730. View

Ben-Baruch A . Partners in crime: TNFα-based networks promoting cancer progression. Cancer Immunol Immunother. 2019; 69(2):263-273. PMC: 11027867. DOI: 10.1007/s00262-019-02435-4. View

Weitzenfeld P, Meshel T, Ben-Baruch A . Microenvironmental networks promote tumor heterogeneity and enrich for metastatic cancer stem-like cells in Luminal-A breast tumor cells. Oncotarget. 2016; 7(49):81123-81143. PMC: 5348381. DOI: 10.18632/oncotarget.13213. View

Askling J, Fored C, Baecklund E, Brandt L, Backlin C, Ekbom A . Haematopoietic malignancies in rheumatoid arthritis: lymphoma risk and characteristics after exposure to tumour necrosis factor antagonists. Ann Rheum Dis. 2005; 64(10):1414-20. PMC: 1755232. DOI: 10.1136/ard.2004.033241. View

10.

Sethi G, Sung B, Aggarwal B . TNF: a master switch for inflammation to cancer. Front Biosci. 2008; 13:5094-107. DOI: 10.2741/3066. View

11.

Ben-Baruch A . The Tumor-Promoting Flow of Cells Into, Within and Out of the Tumor Site: Regulation by the Inflammatory Axis of TNFα and Chemokines. Cancer Microenviron. 2011; 5(2):151-64. PMC: 3399063. DOI: 10.1007/s12307-011-0094-3. View

12.

Aderka D, Engelmann H, Maor Y, Brakebusch C, Wallach D . Stabilization of the bioactivity of tumor necrosis factor by its soluble receptors. J Exp Med. 1992; 175(2):323-9. PMC: 2119112. DOI: 10.1084/jem.175.2.323. View

13.

Huss V, Bower H, Wadstrom H, Frisell T, Askling J . Short- and longer-term cancer risks with biologic and targeted synthetic disease-modifying antirheumatic drugs as used against rheumatoid arthritis in clinical practice. Rheumatology (Oxford). 2021; 61(5):1810-1818. PMC: 9071561. DOI: 10.1093/rheumatology/keab570. View

14.

Soria G, Ofri-Shahak M, Haas I, Yaal-Hahoshen N, Leider-Trejo L, Leibovich-Rivkin T . Inflammatory mediators in breast cancer: coordinated expression of TNFα & IL-1β with CCL2 & CCL5 and effects on epithelial-to-mesenchymal transition. BMC Cancer. 2011; 11:130. PMC: 3095565. DOI: 10.1186/1471-2407-11-130. View

15.

Chen X, Oppenheim J . Targeting TNFR2, an immune checkpoint stimulator and oncoprotein, is a promising treatment for cancer. Sci Signal. 2017; 10(462). DOI: 10.1126/scisignal.aal2328. View

16.

Steeland S, Libert C, Vandenbroucke R . A New Venue of TNF Targeting. Int J Mol Sci. 2018; 19(5). PMC: 5983675. DOI: 10.3390/ijms19051442. View

17.

Miles D, Happerfield L, Naylor M, Bobrow L, Rubens R, Balkwill F . Expression of tumour necrosis factor (TNF alpha) and its receptors in benign and malignant breast tissue. Int J Cancer. 1994; 56(6):777-82. DOI: 10.1002/ijc.2910560603. View

18.

Ziffels B, Pretto F, Neri D . Intratumoral administration of IL2- and TNF-based fusion proteins cures cancer without establishing protective immunity. Immunotherapy. 2018; 10(3):177-188. PMC: 5850986. DOI: 10.2217/imt-2017-0119. View

19.

Seynhaeve A, Hoving S, Schipper D, Vermeulen C, de Wiel-Ambagtsheer G, van Tiel S . Tumor necrosis factor alpha mediates homogeneous distribution of liposomes in murine melanoma that contributes to a better tumor response. Cancer Res. 2007; 67(19):9455-62. DOI: 10.1158/0008-5472.CAN-07-1599. View

20.

Baxevanis C, Voutsas I, Tsitsilonis O, Tsiatas M, Gritzapis A, Papamichail M . Compromised anti-tumor responses in tumor necrosis factor-alpha knockout mice. Eur J Immunol. 2000; 30(7):1957-66. DOI: 10.1002/1521-4141(200007)30:7<1957::AID-IMMU1957>3.0.CO;2-7. View